Effect of mild-to-moderate COVID-19 on the incidence and risk factors for deep vein thrombosis in patients with hip fracture: a retrospective study.

Publication date: Mar 24, 2025

This retrospective study aimed to investigate the effect of mild-to-moderate COVID-19 on the risk of deep vein thrombosis (DVT) in patients with hip fractures. Hip fractures are common in the elderly, and previous research has shown that they accounted for 58. 3% of traumatic fractures in older inpatients during the COVID-19 pandemic in China. Meanwhile, the relationship between COVID-19 and DVT is complex. Some studies have reported that the incidence of DVT in critically ill COVID-19 patients can be as high as 46%, and 20% in those with moderate-to-severe cases. However, the impact of mild-to-moderate COVID-19 on DVT risk in hip fracture patients remains unclear. Adult patients who underwent surgery for hip fractures between December 8, 2022, and January 9, 2023, were included in the study. All patients were tested for SARS-CoV-2 nucleic acid and were assessed for DVT preoperatively using doppler ultrasonography (DUS). Logistic regression was used to identify risk factors for DVT. The records of 98 patients with hip fractures, were included in the analysis, of whom 63 were SARS-CoV-2 positive and 35 were SARS-CoV-2 negative. Pre-operative DUS showed that 36/98 patients (37%) had DVT, including 25/63 (40%) patients with COVID-19, and 11/35 (31%) patients without COVID-19. Multivariable logistic regression analysis showed that pre-operative leukocyte count and platelet-to-lymphocyte ratio (PLR) were independent risk factors for DVT, whereas mild-to-moderate COVID-19 was not an independent risk factor for DVT. In patients with hip fractures, COVID-19 did not significantly increase the risk of DVT. Therefore, in patients with hip fractures, DVT prevention measures should be implemented routinely, regardless of COVID-19 status.

Open Access PDF

Concepts Keywords
China Aged
December Aged, 80 and over
Inpatients China
Pandemic COVID-19
COVID-19
Deep vein thrombosis
Female
Hip fracture
Hip Fractures
Humans
Incidence
Male
Middle Aged
Retrospective Studies
Risk Factors
Risk factors
SARS-CoV-2
SARS-CoV-2
Venous Thrombosis

Semantics

Type Source Name
disease MESH COVID-19
disease MESH deep vein thrombosis
disease MESH critically ill
disease IDO nucleic acid
disease MESH Long Covid
pathway REACTOME Reproduction
drug DRUGBANK Coenzyme M
disease MESH pneumonia
disease MESH syndrome
disease MESH upper respiratory tract infection
disease MESH sore throat
disease MESH respiratory failure
disease MESH shock
disease MESH hypercoagulability
disease IDO blood
disease MESH infections
disease MESH venous thromboembolism
disease MESH pulmonary embolism
disease MESH morbidity
disease IDO process
drug DRUGBANK Enoxaparin
drug DRUGBANK Rivaroxaban
disease MESH contraindications
disease IDO history
disease MESH hypertension
disease MESH stroke
disease MESH coronary artery disease
drug DRUGBANK Fibrinogen Human
drug DRUGBANK Uric Acid
drug DRUGBANK Methionine
disease MESH thrombosis
disease MESH ischemic stroke
disease MESH myocardial infarction
disease MESH thromboembolism
drug DRUGBANK Piroxicam
disease MESH emergency
disease IDO infectivity
disease IDO infection
disease MESH infarction
disease MESH complications
drug DRUGBANK L-Leucine
disease MESH cerebral infarction
disease MESH coronavirus infection
disease MESH embolism
disease MESH reinfection
drug DRUGBANK Guanosine
disease MESH clinical significance
disease MESH hypoxia
disease MESH lung cancer
disease MESH squamous carcinoma
disease MESH Inflammation

Original Article

(Visited 1 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *